Abstract:Objective To observe the effect of short-term continuous subcutaneous insulin infusion（CSII）combined with metformin and semaglutide in the remission of type 2 diabetes mellitus（T2DM）, glycolipid metabolism, islet βcell function, and weight. Methods A total of 42 T2DM patients from the Department of Endocrinology at Geriatric Hospital of Nanjing Medical University were enrolled from September 2022 to December 2023. These patients were given 7-day CSII for intensive therapy during hospitalization, then combined with metformin and semaglutide, and were followed up for 48 weeks. The rate of diabetes remission was calculated. Changes of glycolipid metabolism indicators, islet β cell function, and body mass were compared between remission group and non-remission group. Results After short-term treatment with CSII combined with metformin and semaglutide, the remission rate of T2DM was 54.76% at the 48th of follow-up. Compared with non-remission group, remission group showed more significant improvements in fasting blood glucose, glycated hemoglobin（HbA_1C）, and glycated albumin at the 12th, 24th, and 36th weeks of follow-up（P＜0.05）, and the Disposal Index significantly increased at the 12th week（P＜0.05）. During the follow-up period, body mass and waist circumference decreased significantly （P＜0.05）, and high density lipoprotein cholesterol increased significantly（P＜0.05）. Univariate logistic regression analysis revealed that baseline 2- hour postprandial blood glucose（OR=1.204, 95%CI：1.003-1.446）and medication duration（OR=0.386, 95%CI：0.229-0.650）were influencing factors for remission of T2DM（P＜0.05）. Conclusion Short - term CSII combined with metformin and semaglutide can achieve higher rate of T2DM remission. Combination therapy can correct glycolipid metabolism dysfunction, improve islet β cell function and reduce body weight.